Navigate Biopharma in Carlsbad operates as a Novartis subsidiary and specialty clinical research organization on Rutherford Road, delivering companion diagnostics, biomarker assay development, and end-to-end clinical trial testing for pharmaceutical sponsors. The laboratory's flow cytometry, digital pathology, and ddPCR platforms generate biomarker data across immuno-oncology, cell-therapy, and hormone-pathway programs — the same endocrine biomarkers that clinical providers at Herway Health + Hormones monitor in patient-care settings across Carlsbad. Founded in 2006 and later acquired through Novartis's purchase of Genoptix, Navigate contributed critical assay development and characterization work supporting the regulatory pathway for one of the first FDA-approved CAR-T cell therapies. CAP- and CLIA-certified laboratory operations comply with GxP standards, enabling the CRO to manage global clinical-trial sample logistics, data management, and biostatistical analysis from the single Carlsbad facility. Navigate's biomarker assay portfolio extends beyond oncology into CNS and psychiatric-drug development programs, supporting the neuroscience therapeutic area where clinical investigators at Mindpath Health evaluate emerging treatment protocols for Carlsbad-area patients. Spatial biology and fluorescent immunohistochemistry workflows at the Rutherford Road lab map tumor-microenvironment architecture at single-cell resolution, providing pharmaceutical sponsors with companion-diagnostic data packages required for FDA submissions.